Key result
High expression of lncRNA RP11-757G1.5 was independently associated with poorer disease-specific survival in patients with colorectal cancer (HR 2.015).
Why the study?
The biological functions of long non-coding RNAs in colorectal cancer had not been systematically clarified.
Does RP11-757G1.5 promote proliferation and metastasis in colorectal cancer?
Observational (n=112)
No
Does RP11-757G1.5 promote proliferation and metastasis in colorectal cancer?
Hazard Ratio: 2.015 (95% CI 1.018–5.856)
p-value: p=0.019
The lncRNA RP11-757G1.5 promotes colorectal cancer progression by acting as a ceRNA for miR-139-5p to upregulate YAP1, suggesting it as a potential prognostic biomarker and therapeutic target.
LncRNA signatures may refine CRC prognostic stratification; leaves open validation against standard factors in prospective cohorts before clinical use.
BACKGROUND: Accumulating evidence indicates that long non-coding RNAs (lncRNAs) acting as crucial regulators in tumorigenesis. However, its biological functions of lncRNAs in colorectal cancer (CRC) have not been systematically clarified. METHODS: An unbiased screening was performed to identify disregulated lncRNAs revealed to be implicated in CRC carcinogenesis according to an online-available data dataset. In situ hybridization (ISH), RT-qPCR and RNA fluorescence in situ hybridization (RNA-FISH) were applied to detect RP11-757G1.5 expression in CRC tissues and cell lines. The associations of RP11-757G1.5 with clinicopathological characteristics were analyzed. Their effects on prognosis were analyzed by the Kaplan-Meier analysis, Log-rank test, Univariate and Multivariate Cox regression analysis. The potential biological function of RP11-757G1.5 in CRC was investigated by Colony formation, Edu cell proliferation, Flow cytometry, Wound healing and Transwell assays. Bioinformatics binding site analysis, Luciferase reporter assay, Ago2 immunoprecipitation assays, RNA pull-down assay, RT-qPCR and Western blotting were utilized to demonstrate the mechanism of RP11-757G1.5 acts as a molecular sponge of miR-139-5p to regulate the expression of YAP1. Finally, we further explore the potential role of RP11-757G1.5 in CRC orthotopic xenografts in vivo. RESULTS: We discovered a novel oncogenic lncRNA RP11-757G1.5, that was overexpressed in CRC tissues, especially in aggressive cases. Moreover, up-regulation of RP11-757G1.5 strongly correlated with poor clinical outcomes of patients with CRC. Functional analyses revealed that RP11-757G1.5 promoted cell proliferation in vitro and in vivo. Furthermore, RP11-757G1.5 stimulated cell migration and invasion in vitro and in vivo. Mechanistic studies illustrated that RP11-757G1.5 regulated the expression of YAP1 through sponging miR-139-5p and inhibiting its activity thereby promoting CRC progression and development. CONCLUSIONS: Altogether, these results reveal a novel RP11-757G1.5/miR-139-5p/YAP1 regulatory axis that participates in CRC carcinogenesis and progression.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) conducted an observational in Colorectal cancer (n=112). High RP11-757G1.5 expression vs. Low RP11-757G1.5 expression was evaluated on Disease-specific survival (HR 2.015, 95% CI 1.018-5.856, p=0.019). High expression of lncRNA RP11-757G1.5 was independently associated with poorer disease-specific survival in patients with colorectal cancer (HR 2.015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: